Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT).

[1]  H. Gelderblom,et al.  Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial , 2013, Journal of medical economics.

[2]  D. Esseltine,et al.  Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Atkins,et al.  Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis , 2013, Journal of medical economics.

[4]  O. Linder,et al.  Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study , 2012, European journal of haematology.

[5]  M. Beksac,et al.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.

[6]  K. Reich,et al.  Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta‐analysis of randomized controlled trials , 2012, The British journal of dermatology.

[7]  K. Anderson.  New insights into therapeutic targets in myeloma. , 2011, Hematology. American Society of Hematology. Education Program.

[8]  M. Boccadoro,et al.  Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. , 2011, Blood.

[9]  Nicky J Welton,et al.  NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials , 2011 .

[10]  P. Sonneveld,et al.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.

[11]  G. Hess,et al.  Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland , 2011, Oncology.

[12]  M. Beksac,et al.  Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group , 2011, European journal of haematology.

[13]  M. Boccadoro,et al.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Esseltine,et al.  Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. , 2010, Blood.

[15]  J. Miguel,et al.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. , 2010, The Lancet. Oncology.

[16]  P. Fayers,et al.  Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. , 2010, Blood.

[17]  T. Joensuu,et al.  Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  P. Sonneveld,et al.  Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[20]  Robert McDougall Kerr,et al.  Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib , 2009, American journal of hematology.

[21]  B. Pégourié,et al.  Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Greil,et al.  Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. , 2009, Blood.

[23]  M. Boccadoro,et al.  Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. , 2008, Blood.

[24]  D. Esseltine,et al.  The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma , 2008, British journal of haematology.

[25]  D. Battleman,et al.  Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. , 2008, Clinical advances in hematology & oncology : H&O.

[26]  Jeroen P Jansen,et al.  Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  W. Jędrzejczak,et al.  Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[29]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[30]  B. Pégourié,et al.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.

[31]  K. Takatsuki,et al.  Low‐dose thalidomide plus low‐dose dexamethasone therapy in patients with refractory multiple myeloma , 2007, European journal of haematology.

[32]  A. Onitilo,et al.  Community experience with bortezomib in patients with multiple myeloma , 2007, American journal of hematology.

[33]  P. Sonneveld,et al.  Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma , 2007, British journal of haematology.

[34]  V. Jimenez-Zepeda,et al.  Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? , 2006, European journal of haematology.

[35]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[36]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[37]  M. Oken,et al.  Complete response in multiple myeloma , 2006, Cancer.

[38]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Y. M. van der Linden,et al.  [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. , 2005, Nederlands tijdschrift voor geneeskunde.

[40]  F. Mandelli,et al.  Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. , 2004, Blood.

[41]  A. Whitehead.  A Bayesian Approach to Meta‐Analysis , 2003 .

[42]  T J Ulahannan,et al.  Decision Making in Health and Medicine: Integrating Evidence and Values , 2002 .

[43]  A Whitehead,et al.  Meta‐analysis of ordinal outcomes using individual patient data , 2001, Statistics in medicine.

[44]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[45]  S. Kaasa,et al.  Measurement of health‐related quality of life in multiple myeloma , 1996, British journal of haematology.

[46]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[47]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[48]  B. Barlogie,et al.  Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival : an analysis of 10 549 patients from the International Myeloma Working Group , 2008 .

[49]  Augustin Ferrant,et al.  Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy , 2006 .

[50]  M. Gordon.  Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .

[51]  M. Boccadoro,et al.  Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). , 2004, Haematologica.

[52]  M. Baccarani,et al.  Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. , 2002, Haematologica.

[53]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.